TIO Bio — Rachel Humphrey CMO PR 1.13.2020 SIR.docx

Recent Posts

• Treadwell Announces Initiation of Patient Dosing in TWT-202, a Phase 1b/2 study of PLK4 Inhibitor, CFI-400945, in Patients with Leukemia
• Treadwell Announces Two Presentations at the 2020 ASH Annual Meeting Featuring Clinical Trial Updates on Lead Product Candidate, CFI-400945
• Treadwell Announces Initiation New Clinical Trial CFI 400945
• TIO-Bioventures-Launches-TCRyption-TCR-T-cell-based
• Treadwell-Announces-Initiation-Patient-Dosing-TWT-101-Phase